Investigators reported the development of an estrogen receptor-positive (ER+) breast tumor organoid medium that conserved ER expression, estrogen responsiveness, and dependence, as well as sensitivity to endocrine therapy of ER+ patient-derived xenograft organoids
[Breast Cancer Research]